HeraMED : Investor Presentation - April 2022

Disclaimer

Important notice regarding forward looking statements

This document contains a general summary of the Company and is provided for information purposes only. For full details please review HeraMED Limited ASX page -https://www.asx.com.au/asx/share-price-research/company/HMD

This document does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in HeraMED nor does it constitute financial product advice. This document is not a prospectus, product disclosure statement or other offer document under Australian law or under any other law.

This document has not been filed, registered or approved by regulatory authorities in any jurisdiction.

Certain statements made in this communication, may contain or comprise certain forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, success of business and operating initiatives, changes in the regulatory environment and other government actions, and business and operational risk management. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events

Ongoing Pregnancy Challenges

Doctors/ Providers

Shortage of fundamental services

Expectant Mothers 14+ clinical sessions per pregnancy (Low-risk)

Lack of time and attention

Loss of time away from work / home

Low reliability of analysis

Personal anxiety and stress

Episodic, Reactive, not connected

Lack of continuous support

Pregnancy complications and bad outcomes

Mother and infant mortality rates are rising

Cost of maternity complications*

Opportunity to reduce costs and improve maternity care and outcomes

US$111bn US Maternal Healthcare Market

*Numbers represent US healthcare cost only, global cost are much higherhttps://www.marchofdimes.org/mission/the-economic-and-societal-costs.aspx

PP Depression	Preeclampsia	C-section	Preterm Birth
US$14bn	US$2.2bn	US$9bn	US$26bn
4

HeraCARE A New Era of Connected Maternity Care- Watch the video ->

Expectant Mother

Aggregates and manages medical data of multiple sources, optimizing workflows and allowing healthcare providers to be better informed and effective patient advocates.

Heracare Patient management

HeraBEAT

FHR

SurveysHeracare

CloudEMR Integration

Dashboard

Care Manager